Spruce Biosciences (SPRB)
NASDAQ:SPRB
Want to see SPRB full AI Analyst Report?
SPRB Stock Chart & Stats
$70.30
--
Market closed
$70.30
--
Day’s Range― - ―
52-Week Range$4.78 - $240.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)988.68K
Market Cap
$142.82M
Enterprise Value$23.39M
Total Cash (Recent Filing)$54.08M
Total Debt (Recent Filing)$7.12M
Price to Earnings (P/E)―
Beta-10.18
Next Earnings
Aug 17, 2026EPS Estimate
-5.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-37.60
Shares Outstanding2,752,278
10 Day Avg. Volume2,922,716
30 Day Avg. Volume988,676
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-2.00
Enterprise Value/Market Cap0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.65
Forecast
1Y Price Target
$154.17Price Target Upside119.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-22.85
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet Strength / Low LeverageVery low debt relative to equity reduces interest burden and financial distress risk, giving management optionality to fund clinical programs via non-debt means. For a clinical-stage biotech this durable strength supports R&D continuity, partnership negotiations, and operational flexibility over the next 2–6 months.
Recent Equity Raise Improves RunwayThe roughly $69M gross capital infusion materially extends cash runway, reducing near-term funding pressure and enabling sustained investment in late-stage programs and regulatory submissions. This structural liquidity improvement lowers the immediate need for disruptive financing and supports program execution into late 2026.
Pipeline Refocus With Regulatory ProgressRefocusing on TA-ERT with favorable Type B feedback and an accelerated approval path is a material strategic shift. Disease‑modifying signals and a planned BLA establish a credible route to approval and commercialization, which could transform the company from a purely clinical-stage R&D firm to a product-generating entity if trials and filings succeed.
Bears Say
Persistent Cash Burn And No RevenueSustained negative operating and free cash flow combined with zero recent product revenue means the business cannot self-fund development. This structural cash deficit increases execution risk for clinical programs and heightens reliance on capital markets, which can delay timelines or force concessions if financing conditions tighten.
Reliance On External Financing / Dilution RiskDependence on equity and other external capital exposes shareholders to dilution and creates timing risk. Repeated or large raises can erode ownership and complicate long-term incentive alignment; if market access deteriorates, the company may face constrained options that could slow development or require unfavorable terms.
Loss Of Collaboration And Contingent RevenueTerminating the Kaken deal removes a non-dilutive revenue channel and eliminates milestone/royalty upside tied to tildacerfont. This reduces portfolio optionality and makes the company more dependent on the success of its refocused programs, concentrating clinical and commercial risk onto fewer assets.
Spruce Biosciences News
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $4.78 and its highest was $240.00 in the past 12 months.
What is Spruce Biosciences’s market cap?
Spruce Biosciences’s market cap is $142.82M.
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is Aug 17, 2026 which is in 63 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on May 13, 2026. The company reported -$8.94 earnings per share for the quarter, missing the consensus estimate of -$7.934 by -$1.006.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -5.66.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 2,752,278 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$8.94 in its last earnings report, missing expectations of -$7.934. Following the earnings report the stock price went up 1.562%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Currently, no hedge funds are holding shares in SPRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spruce Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$154.17 (119.30% Upside)
$154.17 (119.30% Upside)
Hedge Fund Trend
Decreased
By 16.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
312.60%
12-Months-Change
Fundamentals
Return on Equity
-155.40%
Trailing 12-Months
Asset Growth
77.47%
Trailing 12-Months
Company Description
Spruce Biosciences
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
SPRB Stock 12 Month Forecast
Average Price Target
$154.17
▲(119.30% Upside)
Technical Analysis
Ownership Overview
66.20% Insiders
1.02% Mutual Funds
12.90% Other Institutional Investors
16.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---